2023
The potential of saliva as an accessible and sensitive sample type for the detection of respiratory pathogens and host immunity
Laxton C, Peno C, Hahn A, Allicock O, Perniciaro S, Wyllie A. The potential of saliva as an accessible and sensitive sample type for the detection of respiratory pathogens and host immunity. The Lancet Microbe 2023, 4: e837-e850. PMID: 37516121, DOI: 10.1016/s2666-5247(23)00135-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSARS-CoV-2Respiratory pathogensPotential of salivaUsefulness of salivaUse of salivaRespiratory specimenRespiratory secretionsDisease burdenImmunological componentsImmunity surveillanceClinical utilityHost immunityClinical useDiagnostic testsNon-invasive natureSalivaCOVID-19 pandemicSample typesMethodological factorsPathogensImmunitySecretion
2022
Reemergence of Invasive Pneumococcal Disease in Germany During the Spring and Summer of 2021
Perniciaro S, van der Linden M, Weinberger DM. Reemergence of Invasive Pneumococcal Disease in Germany During the Spring and Summer of 2021. Clinical Infectious Diseases 2022, 75: 1149-1153. PMID: 35136983, PMCID: PMC9383454, DOI: 10.1093/cid/ciac100.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseIPD surveillance dataIPD casesIPD incidencePneumococcal diseaseNonpharmaceutical interventionsVaccine-serotype invasive pneumococcal diseaseSurveillance dataCoronavirus disease 2019 (COVID-19) pandemicSARS-CoV-2Disease 2019 pandemicVaccine serotypesChildren 0Baseline valuesAge groupsSerotype-specific variationPercentage changeOverall casesIncidenceNPI strategiesIPD levelAge distributionDiseaseBaselineSerotypes
2021
The Impact of Changes in Diagnostic Testing Practices on Estimates of COVID-19 Transmission in the United States
Pitzer VE, Chitwood M, Havumaki J, Menzies NA, Perniciaro S, Warren JL, Weinberger DM, Cohen T. The Impact of Changes in Diagnostic Testing Practices on Estimates of COVID-19 Transmission in the United States. American Journal Of Epidemiology 2021, 190: 1908-1917. PMID: 33831148, PMCID: PMC8083380, DOI: 10.1093/aje/kwab089.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Diagnostic testingRespiratory syndrome coronavirus 2Reproductive numberPercentage of patientsSyndrome coronavirus 2Coronavirus disease 2019Diagnostic testing practicesFraction of casesCOVID-19 transmissionEffective reproductive numberCoronavirus 2Disease 2019Testing practicesCoronavirus diseaseBasic reproductive numberLevel of interventionEstimates of R0Daily number
2019
Limited indirect effects of an infant pneumococcal vaccination program in an aging population
van der Linden M, Imöhl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLOS ONE 2019, 14: e0220453. PMID: 31369597, PMCID: PMC6675109, DOI: 10.1371/journal.pone.0220453.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSerotype 3 invasive pneumococcal diseaseHerd protection effectsIPD casesAge groupsPCV13-type invasive pneumococcal diseaseAdult invasive pneumococcal diseaseAdult pneumococcal vaccinationPneumococcal vaccination programAdults 60 yearsVaccine serotypes 4Years of ageAdult age groupsIndirect protection effectPneumococcal vaccinationPneumococcal diseasePolysaccharide vaccineVaccine recommendationsChildhood vaccinationVaccination programVaccine formulationsAdult coverageAdults 60Protection effectSerotype 4Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany
Perniciaro S, Imöhl M, Fitzner C, van der Linden M. Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany. PLOS ONE 2019, 14: e0210278. PMID: 30625215, PMCID: PMC6326516, DOI: 10.1371/journal.pone.0210278.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseVaccine-type invasive pneumococcal diseaseVT invasive pneumococcal diseaseUnvaccinated childrenSerotype distributionPneumococcal diseaseVaccination statusHigher oddsChildhood invasive pneumococcal diseaseDifferent serotype distributionSerotype of infectionVaccine-type serotypesNon-vaccine serotypesDose of vaccineYears of agePCV10 groupPCV13 groupPCV7 groupVaccine recommendationsAdministration scheduleContinued surveillanceProtective effectParticular serotypeInfectionSignificant predictors
2018
Invasive Pneumococcal Disease in Refugee Children, Germany - Volume 24, Number 10—October 2018 - Emerging Infectious Diseases journal - CDC
Perniciaro S, Imöhl M, van der Linden M. Invasive Pneumococcal Disease in Refugee Children, Germany - Volume 24, Number 10—October 2018 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2018, 24: 1934-1936. PMID: 30226179, PMCID: PMC6154141, DOI: 10.3201/eid2410.180253.Peer-Reviewed Original ResearchReassessing the 1 + 1 pneumococcal conjugate vaccine schedule
Perniciaro S, van der Linden M. Reassessing the 1 + 1 pneumococcal conjugate vaccine schedule. The Lancet Infectious Diseases 2018, 18: 381-382. PMID: 29582765, DOI: 10.1016/s1473-3099(18)30129-4.Peer-Reviewed Original Research
2017
Epidemiology and distribution of 10 superantigens among invasive Streptococcus pyogenes disease in Germany from 2009 to 2014
Imöhl M, Fitzner C, Perniciaro S, van der Linden M. Epidemiology and distribution of 10 superantigens among invasive Streptococcus pyogenes disease in Germany from 2009 to 2014. PLOS ONE 2017, 12: e0180757. PMID: 28719668, PMCID: PMC5515411, DOI: 10.1371/journal.pone.0180757.Peer-Reviewed Original ResearchConceptsSuperantigen genesEmm typesNationwide laboratory-based surveillance studyInvasive S. pyogenes infectionInvasive Streptococcus pyogenes diseaseSignificant associationLaboratory-based surveillance studyFrequent clinical manifestationsS. pyogenes infectionCommon emm typesProportion of isolatesClinical manifestationsClinical complicationsEmm 1Peritoneal fluidPyogenes infectionCerebrospinal fluidSurveillance studyEmm 28Synovial fluidEmm 89S. pyogenesType 3SpeJMost isolates
2016
Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imöhl M. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany. PLOS ONE 2016, 11: e0161257. PMID: 27526117, PMCID: PMC4985133, DOI: 10.1371/journal.pone.0161257.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccineAdjusted vaccine effectivenessTimeliness of vaccinationVaccine effectivenessPost boosterConjugate vaccinePneumococcal diseaseVaccine-type invasive pneumococcal diseaseType invasive pneumococcal diseaseIndirect cohort methodOverall vaccine effectivenessPneumococcal conjugate vaccinationSpecific vaccine effectivenessNumber of dosesYears of ageResidual casesTime of infectionConjugate vaccinationPCV13 serotypesPCV7 serotypesFirst doseIPD casesUnvaccinated childrenVaccination status
2015
Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany
van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLOS ONE 2015, 10: e0131494. PMID: 26132078, PMCID: PMC4488910, DOI: 10.1371/journal.pone.0131494.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGenes, BacterialGermanyHeptavalent Pneumococcal Conjugate VaccineHumansImmunization ProgramsImmunologic SurveillanceInfantInfant, NewbornMaleMiddle AgedPneumococcal InfectionsPneumococcal VaccinesRNA, Ribosomal, 16SSerogroupSerotypingStreptococcus pneumoniaeVaccinationConceptsEarly vaccination periodPneumococcal conjugate vaccinationInvasive pneumococcal diseaseVaccination periodConjugate vaccinationPCV7 serotypesIPD casesPneumococcal diseaseQuellung methodSerotype distributionChildhood pneumococcal conjugate vaccinationNon-vaccinated age groupsAge groupsGerman National Reference CenterPre-vaccination periodSerotype 1Streptococcus pneumoniae isolatesNational Reference CenterMicrobiological diagnostic laboratorySerotype 10AInfant vaccinationVaccine serotypesSerotype 19ASeparate age groupsPneumoniae isolatesIncrease of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era
van der Linden M, Perniciaro S, Imöhl M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infectious Diseases 2015, 15: 207. PMID: 25940580, PMCID: PMC4424534, DOI: 10.1186/s12879-015-0941-9.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePenicillin non-susceptible isolatesNon-PCV13 serotypesNon-susceptible isolatesSerotype 15AVaccination periodSurveillance of IPDClonal complexesChildhood pneumococcal conjugate vaccinationGerman National Reference CenterEarly vaccination periodHigher-valent vaccinesPneumococcal conjugate vaccinationNational Reference CenterConclusionsThe prevalenceConjugate vaccinationSerotype 23BPneumococcal diseaseChildhood vaccinationVaccination eraSurveillance periodSerogroups 23BackgroundThis studyReference centerVaccination formulationsPneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany
Imöhl M, Möller J, Reinert R, Perniciaro S, van der Linden M, Aktas O. Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany. BMC Infectious Diseases 2015, 15: 61. PMID: 25885764, PMCID: PMC4335684, DOI: 10.1186/s12879-015-0787-1.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseMeningitis casesPneumococcal meningitisQuellung reactionGerman National Reference CenterNeufeld Quellung reactionPre-PCV7 periodPneumococcal conjugate vaccinePost-vaccination periodCase mortality rateNational Reference CenterAntibiotic nonsusceptibilityIPD isolatesPneumococcal diseaseVaccination recommendationsVaccine recommendationsConjugate vaccineVaccine serotypesBroth microdilution methodVaccine effectsNationwide surveillancePneumococcal isolatesSerotype prevalenceReference centerMortality rate
2013
Epidemiology of Streptococcus pneumoniae Serogroup 6 Isolates from IPD in Children and Adults in Germany
van der Linden M, Winkel N, Küntzel S, Farkas A, Perniciaro S, Reinert R, Imöhl M. Epidemiology of Streptococcus pneumoniae Serogroup 6 Isolates from IPD in Children and Adults in Germany. PLOS ONE 2013, 8: e60848. PMID: 23593324, PMCID: PMC3621884, DOI: 10.1371/journal.pone.0060848.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSerotypes 6BSerogroup 6 isolatesSerotypes 6ASerotype 6CChildhood pneumococcal conjugate vaccinationSerotype 6DPneumococcal conjugate vaccinationPneumococcal conjugate vaccineLow resistance ratesSerotype 6C isolatesConjugate vaccinationPCV periodPCV7 vaccinationPneumococcal diseaseConjugate vaccineMultilocus sequence typingChildhood vaccinationResistance ratesVaccinationPrevalenceSequence typingStatistical significanceAntibiotic resistanceSerotype 6D.